Faculty
Sameek Roychowdhury, MD, PhD
Associate Professor, Department of Internal Medicine
Division of Medical Oncology
Medical Director, CLIA?Certified Cancer Genomics Laboratory
The Ohio State University, James Cancer Hospital and Comprehensive Cancer Center
Columbus, OH
Carlos L. Arteaga, MD
Professor of Medicine
Director, UTSW Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
James M. Cleary, MD, PhD
Clinical Investigator, Hale Family Center for Pancreatic Cancer Research
Department of Medical Oncology, Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Boston, MA
Activity Planners
Julie Blum, PhD
Director, Clinical Content
Med-IQ
Baltimore, MD
Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD
Amy Sison
Director of CME
Med-IQ
Baltimore, MD
Kathryn Schaefer, MSN, RN, CPHRM
Associate Director, Education Quality and Compliance
Med-IQ
East Lansing, MI
Learning Objectives
Upon completion, participants should be able to:
Target Audience
This activity is intended for oncology professionals including physicians, physician assistants, nurse practitioners, nurses, and researchers.
Statement of Need
Advances with technology and an increased understanding of the molecular pathways that drive oncogenesis have led to the development of novel therapies targeting fibroblast growth factor receptor (FGFR) aberrations in multiple tumor types. Several FGFR inhibitors are producing profound and durable responses in cancer treatment. An FGFR inhibitor recently gained FDA approval in the treatment of urothelial cancer, and other approvals are anticipated. Optimizing the clinical use of FGFR inhibitors will depend on the appropriate selection of patients who are most likely to benefit from these agents as well as the selection of the optimal FGFR-targeting agent, taking into account the selectivity of the agents, efficacy and toxicity profiles, and the design and implementation of novel strategies to overcome resistance mechanisms and further improve response rates. To that end, developing a clear understanding of the emerging research and the evolving landscape of FGFR inhibitors in various tumor types is needed to effectively optimize the use these agents in clinical practice.
Providership Satement
Provided by Med-IQ.
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Contracted research: Lilly USA, LLC, Pfizer, Inc.
Ownership interest (stocks/stock options – excluding mutual funds): Provista
James M. Cleary, MD, PhD
Consulting fees/advisory boards: Syros Pharmaceuticals, Inc.
Contracted research: AbbVie Inc., AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, Esperas Pharma Inc., F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co., Inc., Merus
Sameek Roychowdhury, MD, PhD
Consulting fees/advisory boards: Incyte Corporation, Merck & Co., Inc.
The peer reviewers and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity
Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.
System Requirements
Desktop
Mobile
Applications & Software
For technical assistance, please refer to our Support Manual.
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.
View reference list.
Click “Continue” to proceed through this activity and/or receive credit.
By clicking "Continue," you confirm that you have reviewed the CME information.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.